Leman Biotech

Executive Summary

Leman Biotech is a clinical-stage biotechnology company pioneering next-generation metabolic cancer immunotherapies. Based in Suzhou, China, the company leverages its proprietary Meta 10 metabolic reprogramming platform and AI-driven drug discovery to develop therapies that reinvigorate exhausted T cells and enhance cell-based treatments. Its pipeline focuses on solid tumors and hematological malignancies, with lead candidates including metabolically armored CAR-T and TIL therapies. By targeting metabolic vulnerabilities in the tumor microenvironment, Leman aims to overcome key resistance mechanisms that limit current immunotherapies, potentially offering durable responses in refractory patient populations. The company has advanced its lead program into Phase 1 clinical trials, with initial dose-escalation data expected in the coming quarters. Leman's approach addresses a critical gap in cancer immunotherapy—T cell exhaustion—by reprogramming cellular metabolism. While still in early development, the platform has attracted interest from academic and industry partners. Key upcoming milestones include initial safety and efficacy readouts, potential IND filings for next-generation candidates, and partnership opportunities to expand pipeline reach. Conviction is moderate given the early stage, but the scientific rationale and unmet need support continued monitoring.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1 data readout for lead CAR-T candidate (LMB-001) in solid tumors65% success
• Q4 2026IND submission for second-generation TIL therapy targeting metabolic pathways75% success
• TBDStrategic partnership or licensing deal for Meta 10 platform with global pharma30% success